BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 34156606)

  • 1. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 3. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
    Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
    Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 7. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
    J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
    Nasser M; Larrieu S; Boussel L; Si-Mohamed S; Bazin F; Marque S; Massol J; Thivolet-Bejui F; Chalabreysse L; Maucort-Boulch D; Hachulla E; Jouneau S; Le Lay K; Cottin V
    Respir Res; 2021 May; 22(1):162. PubMed ID: 34030695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [No Abstract]   [Full Text] [Related]  

  • 12. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne].
    Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A
    Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
    Olson AL; Gifford AH; Inase N; Fernández Pérez ER; Suda T
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI; Park H; Park S; Shin JY; Kim YH
    BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
    Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.
    Inoue Y; Kaner RJ; Guiot J; Maher TM; Tomassetti S; Moiseev S; Kuwana M; Brown KK
    Chest; 2020 Aug; 158(2):646-659. PubMed ID: 32268131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.